ERBB2 and breast carcinoma: In summary, this first proteomic profiling of SKBR3/HER2+ breast cancer cells treated with Lapatinib and Ipatasertib provided a comprehensive view of their combined impact on cellular biology and shed light on the molecular and possible off-target effects of kinase inhibitors.